行情

MNKD

MNKD

曼恩凯德生物医疗
NASDAQ

实时行情|Nasdaq Last Sale

1.440
0.000
0.00%
盘后: 1.440 0 0.00% 17:49 06/02 EDT
开盘
1.460
昨收
1.440
最高
1.470
最低
1.390
成交量
219.40万
成交额
--
52周最高
1.880
52周最低
0.8000
市值
3.07亿
市盈率(TTM)
-6.2473
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MNKD价格均价为3.000,最高价位4.000,最低价为2.500。

EPS

MNKD 新闻

更多
Introducing MannKind (NASDAQ:MNKD), The Stock That Tanked 94%
Simply Wall St. · 05/25 16:12
MannKind (MNKD) Stock Could Nearly Double in the Next Year, Says Analyst
It has been a rough five years for investors of diabetes-focused biotech MannKind (MNKD). Over the period, shares of the company have declined by 94%. However, according to H.C. Wainwright analyst Oren Livnat, there might be a two-pronged opportunity on the ho
SmarterAnalyst · 05/20 00:44
Edited Transcript of MNKD earnings conference call or presentation 6-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 05/07 09:36
MannKind Corporation's (MNKD) CEO Michael Castagna on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/07 03:47
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 21:15
MannKind Corporation Reports 2020 First Quarter Financial Results
GlobeNewswire · 05/06 21:00
MannKind Q1 EPS $(0.040) Beats $(0.060) Estimate, Sales $16.200M Beat $14.790M Estimate
MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.040) per share which beat the analyst consensus estimate of $(0.060) by 33.33 percent. This is a 50 percent increase over losses of $(0.080) per share from the same
Benzinga · 05/06 20:01
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 14:36

所属板块

生物技术和医学研究
+0.79%
制药与医学研究
+0.53%

热门股票

代码
价格
涨跌幅

MNKD 简况

MannKind Corporation是一家生物制药公司。该公司专注于发现和开发用于疾病治疗的产品,如糖尿病。其候选产品是AFREZZA。AFREZZA是一种用于控制I型和II型糖尿病成年人高血糖的吸入性胰岛素,有助于血糖控制。AFREZZA由从便携式吸入器输送的人胰岛素干燥制剂组成。AFREZZA利用其Technosphere配方技术。Technosphere是一种可以允许口服吸入各种药物的药物递送平台。Technosphere粉末基于该公司的富马酰二酮哌嗪(FDKP)。FDKP是在酸性条件下自装配成小颗粒的氢(pH)敏感有机分子的潜力。该公司还创造一系列呼吸动力干粉吸入器。其吸入器包括可重复使用(慢性治疗)和一次性(急性治疗)两种类别。
展开

微牛提供MannKind Corporation(NASDAQ-MNKD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MNKD股票新闻,以帮助您做出投资决策。